Defence Therapeutics Inc. (CNSX: DTC)
Health Care · Biotechnology · CA
CA$0.51
+8.51% today · -31.1% 1Y
Defence Therapeutics Inc. (CNSX: DTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.07M and employs 5 people.
Over the last twelve months the share price has lost 31.1%, trading between 0.37 and 0.93.
Tweenvest scores Defence Therapeutics Inc. across four factors: quality 19/100. Its strongest factor is quality.
DTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.07M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 1.33
- 52-week high
- CA$0.93
- 52-week low
- CA$0.37
- Avg volume (3M)
- —
- Shares outstanding
- 75.79M
- Employees
- 5
- Next earnings
- —
About Defence Therapeutics Inc.
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
- Founded
- 2017
- Listed since
- May 10, 2021
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.85 | +0.34% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.74 | +0.09% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.56 | +0.30% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.22 | -1.96% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.